23 February 2018
BPC-A-24-2018_rev2

Draft agenda

24th meeting of the Biocidal Products Committee (BPC)

6 – 7 March 2018

ECHA Conference Centre, Annankatu 18, Helsinki

Starts on 6 March at 09:30, ends on 7 March at 13:00

1. – Welcome and apologies

2. – Agreement of the agenda

BPC-A-24-2018
For agreement

3. – Declarations of potential conflicts of interest to agenda items

4. – Agreement of the minutes and review of actions from BPC-23

BPC-M-23-2017
For agreement

5. – Administrative issues

5.1. Housekeeping issues

For information

5.2. Other administrative issues and report from other Committees

BPC-24-2018-01
For information

5.3. Mandate of the Ad-hoc Working Group Environmental Exposure

BPC-24-2018-16
For agreement

6. – Work programme for BPC

6.1. Revised BPC Work Programme 2018-2019

BPC-24-2018-02

For information

6.2. Outlook for BPC

BPC-24-2018-03

For information

6.3. New requests from the Commission related to Article 38 and Article 75(1)(g)

BPC-24-2018-17

BPC-24-2018-18

For information and agreement

7. – Applications for approval of active substances*

7.1. Working procedure for active substance approval

BPC-24-2018-04

For agreement

7.2. Draft BPC opinion on salicylic acid for PT 2, 3, 4

Previous discussion(s): WG-V-2017

PT2: BPC-24-2018-05A, B, C

PT3: BPC-24-2018-06A, B, C

PT4: BPC-24-2018-07A, B, C

For adoption

7.3. Draft BPC opinion on 2-Phenoxyethanol for PT 1, 2, 4

Previous discussion(s): WG-IV-2017

PT1: BPC-24-2018-08A, B, C

PT2: BPC-24-2018-09A, B, C

PT4: BPC-24-2018-10A, B, C

For adoption

* For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft assessment report (AR) which may cover more than one PT (denoted by B) and a document containing open issues covering all the PTs to be discussed for that substance (denoted by C).

7.4. Revised Assessment Report following the submission of data after active substance approval:

7.4.1. Transflutrhin for PT 18

BPC-24-2018-11A, B

For agreement

7.4.2. Bacillus thuringiensis subsp. Kurstaki for PT 18 and for copper thiocyanate, dicopper oxide and copper flakes (coated with aliphatic acid) for PT 21

For information

7.5. Assessment of endocrine disrupting properties in active substance approval

BPC-24-2018-19

For discussion and agreement

Item 8 – Union authorisation[†]

8.1 Update on Union authorisation

8.2 Draft BPC opinion on Union authorisation application for product families containing iodine / PVP-iodine

BPC-24-2018-12A, B, C and D

For adoption

8.3 Iodate in biocidal products containing iodine / PVP-iodine as active substance: TAB entry

BPC-24-2018-13

For agreement

Item 9 – Dermal absorption

9.1 Guidance document on dermal absorption

BPC-24-2018-14

For agreement

[†] For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft Summary of Product Characteristics (SPC) (denoted by B), a draft product assessment report (PAR) (denoted by C) and a document containing open issues to be discussed for the biocidal product or biocidal product familiy (denoted by D).

Item 10 – Assessment of relevant impurities

10.1 ECHA proposal for timelines on preparing guidance on the assessment of relevant impurities

BPC-24-2018-15

For discussion and agreement

Item 11 – Treated articles

11.1 Risk assessment for treated articles / materials at active substance approval stage and the consequences for risk mitigation

BPC-24-2018-20

For discussion

Item 12 – Any other business

12.1 Harmonised List of Endpoints for pyrethroid metabolites

BPC-24-2018-21

For information

Item 13 – Action points and conclusions

For agreement

Provisional time schedule for the

24th meeting of the Biocidal Products Committee (BPC)

ECHA Conference Centre, Annankatu 18, Helsinki

6 March 2018: starts at 09:30; 7 March ends at 13:00

Please note that the time schedule indicated below are provisional and subject to possible change. The schedule is distributed to participants on a preliminary basis. If needed, follow-up discussions may take place on the following day for BPC opinions.

Tueday 6 March: morning session

Items 1-5	Opening items and administrative issues
Item 6	Work programme of the BPC 2018-19
Item 7.2	Draft BPC opinion on salicylic acid for PT 2, 3, 4

Tuesday 6 March: afternoon session

Item 7.3	Draft BPC opinion on 2-Phenoxyethanol for PT 1, 2, 4
Item 7.4	Revised Assessment Report following the submission of data after active substance approval:
	7.4.1. Transflutrhin for PT 18
	7.4.2 Bacillus thuringiensis subsp. Kurstaki for PT 18 and for copper thiocyanate, dicopper oxide and copper flakes (coated with aliphatic acid) for PT 21
Item 7.1	Working procedure for active substance approval
Item 7.5	Assessment of endocrine disrupting properties in active substance approval
Item 9.1	Guidance document on dermal absorption
Item 10.1	ECHA proposal for timelines on preparing guidance on the assessment of relevant impurities

Wednesday 7 March: morning session

Item 8.1	Update on Union authorisation
Item 8.2	Draft BPC opinion on Union authorisation application for product families containing iodine / PVP-iodine
Item 8.3	Iodate in biocidal products containing iodine / PVP-iodine as active substance: TAB entry
Item 11.1	Risk assessment for treated articles / materials at active substance approval stage and the consequences for risk mitigation
Item 12	AOB:
	12.1: Harmonised List of Endpoints for pyrethroid metabolites
Item 13	Action points and conclusions

End of meeting

o0o